Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharvaris NV PHVS

Healthcare Biotechnology
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).

Recent & Breaking News (NDAQ:PHVS)

Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire August 7, 2023

Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit

GlobeNewswire July 21, 2023

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

GlobeNewswire June 26, 2023

Pharvaris Announces $70 Million Private Placement Financing

GlobeNewswire June 20, 2023

Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

GlobeNewswire June 10, 2023

Pharvaris Announces Annual Meeting of Shareholders

GlobeNewswire June 1, 2023

Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire May 8, 2023

Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop

GlobeNewswire May 6, 2023

Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire April 5, 2023

Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC

GlobeNewswire March 18, 2023

Pharvaris to Present in Upcoming March Investor Conferences

GlobeNewswire March 2, 2023

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting

GlobeNewswire February 24, 2023

Pharvaris to Present at SVB Securities Global Biopharma Conference

GlobeNewswire February 8, 2023

Pharvaris Provides Regulatory, Clinical, and Corporate Updates

GlobeNewswire January 9, 2023

Pharvaris Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire December 8, 2022

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

GlobeNewswire December 8, 2022

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022

GlobeNewswire November 10, 2022

Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop

GlobeNewswire October 7, 2022

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

GlobeNewswire September 30, 2022

Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium

GlobeNewswire September 16, 2022